


### Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the present application:

1. (Currently amended) A pharmaceutical composition comprising a compound having the following formula (I):




wherein:

- (a) X is CH or N;
- (b) R<sub>1</sub> is hydrogen, alkyl, ~~aralkyl~~ aralkyl, heteroaralkyl, alkenyl, aralkenyl, heteroaralkenyl, aryl, or heteroaryl;
- (c) R<sub>2</sub> is hydrogen, alkyl, ~~aralkyl~~ aralkyl, aryl, or heteroaryl;
- (d) R<sub>2</sub> is hydrogen unless R<sub>2</sub> is methyl, in which case R<sub>2</sub> is also methyl;
- (e) R<sub>3</sub> has the following formula (III):



wherein:

- (i)  $R_4$  is hydrogen, alkyl, halo, hydroxy, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, or hydroxymethyl;
- (ii)  $R_5$  is hydrogen, alkyl, halo, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, amino, aminocarbonyl, aminosulfonyl, or hydroxymethyl;
- (iii)  $R_6$  is alkyl, halo, alkoxy, perfluoroalkyl, perfluoroalkoxy, or nitro;
- (iv)  $R_4$  and  $R_5$  when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;
- (v)  $R_5$  and  $R_6$  when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;
- (f) L is selected from the group consisting of  $-(CH_2)_m-$ , where m is an integer from 1 to 6, and an alkyl substituted hydrocarbyl moiety of the formula (IV):



wherein:

- (i) n is 0, 1 or 2;
- (ii)  $R_7$  and  $R_8$  are hydrogen, methyl or ethyl;
- (iii)  $R_9$  and  $R_9'$  are both hydrogen, methyl or ethyl;
- (iv) if n is 1 and  $R_7$  or  $R_8$  is methyl or ethyl, then  $R_9$  and  $R_9'$  are hydrogen;

(v) if n is 1 and R7 and R8 are hydrogen, then R9 and R9' are methyl or ethyl; and

(vi) if n is 2, then R9 and R9' are hydrogen and one or both of R7 and R8 are methyl or ethyl.

and pharmaceutically acceptable salts and esters thereof.

2. (Original) The pharmaceutical composition of claim 1, wherein R<sub>2</sub> and R<sub>2</sub>', are both hydrogen.
3. (Original) The pharmaceutical composition of claim 1, wherein R<sub>4</sub> is selected from the group consisting of hydrogen, halo, and alkoxy.
4. (Currently amended) The pharmaceutical composition of claim 1, wherein R<sub>5</sub> is selected from the group consisting of hydrogen, alkyl, halo, alkoxy, and perfluoroalkyl [[:]] .
5. (Original) The pharmaceutical composition of claim 1, wherein R<sub>6</sub> is selected from the group consisting of alkyl, halo, alkoxy, and perfluoroalkyl.
6. (Currently amended) The pharmaceutical composition of claim 1, wherein R<sub>4</sub> and R<sub>5</sub> ~~when taken together form a naphthalene ring~~ ~~and~~ .
7. (Original) The pharmaceutical composition of claim 1, wherein R<sub>5</sub> and R<sub>6</sub> when taken together are selected from the group consisting of a methylenedioxy group and an ethylenedioxy group.
8. (Original) The pharmaceutical composition of claim 1, wherein L is an alkyl substituted hydrocarbyl moiety of formula (IV).
9. (Original) The pharmaceutical composition of claim 1, comprising a pharmaceutically acceptable excipient.

10. (Withdrawn) A method of treating a psychiatric or neurological condition, comprising the step of administering a therapeutic dose of the pharmaceutical composition of claim 1 to a patient in need thereof.
11. (Withdrawn) The method of claim 10, wherein the therapeutic dose is administered by an administrative route selected from the group consisting of intravenous infusion, oral, topical, intraperitoneal, intravesical, transdermal, nasal, rectal, vaginal, intramuscular, intradermal, subcutaneous and intrathecal routes.
12. (Withdrawn) The method of claim 10, wherein the therapeutic dose is in the range of 0.0001 mg/kg to 60 mg/kg.
13. (Withdrawn) The method of claim 10, wherein the condition being treated is a psychiatric condition.
14. (Withdrawn) The method of claim 10, wherein the condition being treated is pain.
15. (Withdrawn) The method of claim 10, wherein the condition being treated is emesis.
16. (Withdrawn) The method of claim 10, wherein the condition being treated is neurodegeneration.

Claims 17-18 (canceled).

19. (Previously presented) The pharmaceutical composition of claim 1, wherein the compound is selected from the group consisting of:
- 1-{4-[4-(4-Fluorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;
- 1-{3-[4-(3,4-Dichlorophenyl)piperazin-1-yl]propyl}-1,5,6,7-tetrahydroindol-4-one;
- 1-{4-[4-(2,4-Dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;
- 1-{4-[4-(3-Chloro-4-fluorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;
- 1-{4-[4-(4-Bromophenyl)piperazine-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one; and
- 1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one

20. (Previously presented) The pharmaceutical composition of claim 19, wherein the compound is 1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one.
21. (Withdrawn) The method of claim 10, wherein the pharmaceutical composition comprises 1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one.
22. (New) The pharmaceutical composition of claim 5, wherein R<sub>6</sub> is halo.
23. (New) The pharmaceutical composition of claim 22, wherein R<sub>5</sub> and R<sub>6</sub> are halo.
24. (New) The pharmaceutical composition of claim 1, wherein R<sub>6</sub> is C<sub>2</sub>-C<sub>10</sub> alkyl.
25. (New) A method of treating a psychiatric or neurological condition, comprising the step of administering a therapeutic dose of the pharmaceutical composition of claim 19 to a patient in need thereof.